[go: up one dir, main page]

IL112459A - Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases - Google Patents

Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases

Info

Publication number
IL112459A
IL112459A IL11245995A IL11245995A IL112459A IL 112459 A IL112459 A IL 112459A IL 11245995 A IL11245995 A IL 11245995A IL 11245995 A IL11245995 A IL 11245995A IL 112459 A IL112459 A IL 112459A
Authority
IL
Israel
Prior art keywords
manufacture
mometasone furoate
medicament
lung diseases
airway passage
Prior art date
Application number
IL11245995A
Other languages
English (en)
Other versions
IL112459A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112459(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL112459A0 publication Critical patent/IL112459A0/xx
Publication of IL112459A publication Critical patent/IL112459A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11245995A 1994-01-27 1995-01-26 Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases IL112459A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18837294A 1994-01-27 1994-01-27

Publications (2)

Publication Number Publication Date
IL112459A0 IL112459A0 (en) 1995-03-30
IL112459A true IL112459A (en) 1999-04-11

Family

ID=22692858

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11245995A IL112459A (en) 1994-01-27 1995-01-26 Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases

Country Status (29)

Country Link
EP (6) EP1174139B1 (xx)
JP (6) JP3480736B2 (xx)
KR (1) KR100234864B1 (xx)
CN (4) CN101164542A (xx)
AT (5) ATE519489T1 (xx)
AU (1) AU691880B2 (xx)
CA (1) CA2182086C (xx)
CO (1) CO4340692A1 (xx)
CY (2) CY2616B2 (xx)
CZ (1) CZ219196A3 (xx)
DE (1) DE69526425T2 (xx)
DK (3) DK0740550T3 (xx)
ES (3) ES2173947T3 (xx)
FI (2) FI122395B (xx)
HK (4) HK1040911B (xx)
HU (1) HU227837B1 (xx)
IL (1) IL112459A (xx)
MX (1) MX9602246A (xx)
MY (1) MY114665A (xx)
NO (2) NO314535B1 (xx)
NZ (1) NZ279979A (xx)
PE (1) PE44995A1 (xx)
PL (1) PL315575A1 (xx)
PT (3) PT1174138E (xx)
SG (1) SG47387A1 (xx)
SK (1) SK283338B6 (xx)
TW (1) TW329387B (xx)
WO (1) WO1995020393A1 (xx)
ZA (1) ZA95637B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
EP0923376B1 (en) 1996-05-09 2004-11-03 Amrad Operations Pty.,Ltd. Use of steroids for treatment of asthma and airway diseases
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
DK0927037T3 (da) * 1996-08-29 2001-09-24 Schering Corp Aerosolformuleringer af mometason-furoat uden chlorfluorcarbonhydrider
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
IL131640A0 (en) * 1997-03-20 2001-01-28 Schering Corp Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
EP1033991B1 (en) * 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
AU7859800A (en) * 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
CN101518537A (zh) 2000-12-22 2009-09-02 日本新药株式会社 炎症性呼吸道疾病的预防/治疗剂
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
US20070053843A1 (en) * 2003-10-28 2007-03-08 Dawson Michelle L Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2005072704A2 (en) * 2004-01-21 2005-08-11 Schering Corporation Method of treating acute rhinosinusitis
JP4893999B2 (ja) 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
LT3354276T (lt) 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
HRP20201231T1 (hr) * 2008-08-20 2020-12-11 The Regents Of The University Of California Kortikosteroidi, namijenjeni liječenju upalnih bolesti gastrointestinalnog sustava
EP2349206A2 (en) * 2008-10-10 2011-08-03 Schering Corporation Corticosteroid compositions and methods of treatments thereof
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种吸入用糠酸莫米松混悬液组合物
BR112020016817A2 (pt) 2018-02-23 2020-12-15 Glenmark Specialty S.A. Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN113933415B (zh) * 2021-09-30 2023-03-24 北京阳光德美医药科技有限公司 一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en) 1985-07-31 1990-11-27 Vortran Medical Technology, Inc. Inhalation device and method
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) * 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
DE69034007T2 (de) * 1989-04-28 2003-05-08 Riker Laboratories Inc., Northridge Inhalationsvorrichtung für Trockenpulver
EP0636362B1 (en) * 1990-03-23 1999-12-22 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
DE69104991T2 (de) * 1990-09-10 1995-04-20 Schering Corp Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DK0512090T4 (da) * 1990-10-16 2007-01-15 Sonoran Desert Chemicals Llc Behandling af inflammation
CA2094266C (en) * 1990-10-18 1999-06-01 Robert K. Schultz Aerosol formulations of beclomethasone-17,21-dipropionate
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
CZ271493A3 (en) * 1991-06-10 1994-07-13 Schering Corp Aerosol preparations without chlorofluorinated hydrocarbons
ZA924163B (en) * 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
SG43834A1 (en) * 1991-06-26 1997-11-14 Schering Corp Inhalation device for powdered medicaments
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
ATE128350T1 (de) * 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2421976C (en) * 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
ATE145819T1 (de) * 1992-03-10 1996-12-15 Fisons Plc Inhalierbare arzneimittel
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
HU9602043D0 (en) 1996-09-30
JP3480736B2 (ja) 2003-12-22
DE69526425D1 (de) 2002-05-23
EP1174139B1 (en) 2011-09-21
DK1174138T3 (da) 2011-11-21
DE69526425T2 (de) 2002-12-05
EP1174139A2 (en) 2002-01-23
NO314535B1 (no) 2003-04-07
ATE525075T1 (de) 2011-10-15
EP1192946A1 (en) 2002-04-03
AU691880B2 (en) 1998-05-28
JP5247265B2 (ja) 2013-07-24
ES2369516T3 (es) 2011-12-01
IL112459A0 (en) 1995-03-30
CO4340692A1 (es) 1996-07-30
ATE531364T1 (de) 2011-11-15
JPH11286447A (ja) 1999-10-19
CN1531967A (zh) 2004-09-29
MX9602246A (es) 1997-07-31
CN100441192C (zh) 2008-12-10
NO328698B1 (no) 2010-04-26
KR100234864B1 (ko) 1999-12-15
SG47387A1 (en) 1998-04-17
NO963132L (no) 1996-09-26
EP2156840A3 (en) 2010-05-19
ES2368827T3 (es) 2011-11-22
SK82296A3 (en) 1997-03-05
CA2182086A1 (en) 1995-08-03
EP0740550B1 (en) 2002-04-17
EP1174138A3 (en) 2002-01-30
JP2003313128A (ja) 2003-11-06
PT1174138E (pt) 2011-10-03
EP2156840B1 (en) 2011-08-10
EP1174138A2 (en) 2002-01-23
MY114665A (en) 2002-12-31
EP2156840A2 (en) 2010-02-24
TW329387B (en) 1998-04-11
NO20025002L (no) 1996-09-26
CY2616B2 (en) 2012-05-23
NZ279979A (en) 2001-03-30
PL315575A1 (en) 1996-11-12
JP2008031184A (ja) 2008-02-14
ATE216243T1 (de) 2002-05-15
FI123580B (fi) 2013-07-31
PE44995A1 (es) 1995-12-18
SK283338B6 (sk) 2003-06-03
ZA95637B (en) 1995-07-26
CZ219196A3 (en) 1996-12-11
DK0740550T3 (da) 2002-06-24
FI962828A0 (fi) 1996-07-12
FI20115742L (fi) 2011-07-08
JPH09501700A (ja) 1997-02-18
HUT74884A (en) 1997-02-28
HK1040912A1 (en) 2002-06-28
CN101164542A (zh) 2008-04-23
FI962828L (fi) 1996-07-12
EP1174138B1 (en) 2011-08-03
PT2156840E (pt) 2011-10-18
HK1040918A1 (en) 2002-06-28
ATE519489T1 (de) 2011-08-15
NO20025002D0 (no) 2002-10-17
DK2156840T3 (da) 2011-11-21
FI122395B (fi) 2011-12-30
EP1201242B1 (en) 2011-11-02
CY2617B2 (en) 2012-05-23
HU227837B1 (en) 2012-05-02
JP2008285497A (ja) 2008-11-27
NO963132D0 (no) 1996-07-26
EP1201242A2 (en) 2002-05-02
CN100358528C (zh) 2008-01-02
AU1727195A (en) 1995-08-15
EP0740550A1 (en) 1996-11-06
EP1174139A3 (en) 2002-01-30
PT740550E (pt) 2002-08-30
HK1040911A1 (en) 2002-06-28
CN101156860A (zh) 2008-04-09
CA2182086C (en) 2000-04-11
HK1041829A1 (en) 2002-07-26
EP1201242A3 (en) 2003-12-03
WO1995020393A1 (en) 1995-08-03
ES2173947T3 (es) 2002-11-01
CN1139384A (zh) 1997-01-01
JP2012036222A (ja) 2012-02-23
HK1135331A1 (en) 2010-06-04
ATE518520T1 (de) 2011-08-15
HK1040911B (en) 2011-11-18

Similar Documents

Publication Publication Date Title
IL112459A (en) Use of mometasone furoate in the manufacture of a medicament for treating airway passage and lung diseases
IL125534A (en) Unit dose of budesonide and use thereof for nasal administration
PL372118A1 (en) Composition for inhalation
Benton et al. Experience with a metered-dose inhaler with a spacer in the pediatric emergency department
TW200602054A (en) Use of compounds in a dry powder inhaler
DK0533896T3 (xx)
WO1992011025A3 (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
Weller Inhaler devices for use in asthma care
Heath et al. Information from your family doctor: Taking care of chronic bronchitis
Blaiss Aerosols and delivery devices in asthma management
Blanco et al. AD Loppow et al.
Sagalovich et al. Efficacy of combined therapy of patients with destructive tuberculosis of the lung dependent on the time of rifampicin use.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired